Australia's Clarity Pharmaceuticals rises on successful trial recruitment

Clarity Pharmaceuticals

17/07/2025 03:39

** Shares of Clarity Pharmaceuticals CU6.AX rise as much as 9.7% to A$3.74, their highest level since February 14

** Stock among top performers on the ASX 200 benchmark

** Pharmaceutical firm says the Co-PSMA trial has completed study enrolment

** The study will be evaluating the performance of co's '64Cu-SAR-bisPSMA' product for detecting the recurrence of prostate cancer

** Says diagnostic capabilities of its product against the standard care have been demonstrated in two prospective clinical trials, now followed by two Phase III registrational trials

** Data generated thus far on the product in the two clinical trials are very encouraging - principal investigator in the Co-PSMA trial

** Stock last up 3.2% with YTD losses of 15.6%

 (Reporting by Sneha Kumar in Bengaluru)

 ((Sneha.kumar@thomsonreuters.com;))